Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$8.02−0.60 (-6.96%)

Close on Nov 12, 2026Market cap $291.06MP/E –Yield –

Evommune total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Evommune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVMN.

Revenue growth-100.0% · median 320.4%

Advertisement
300 × 250

See a number that looks wrong?